Literature DB >> 28263459

Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology.

Charles S Venuto1,2, Andrew H Talal3.   

Abstract

Although the importance of the liver in clinical pharmacology is widely recognized, little is known in humans concerning its function in vivo at the hepatocyte level and how pharmacological functions are altered in the setting of advanced liver disease. Several recent proof-of-principle studies with first-generation DAAs have demonstrated the feasibility of serial liver sampling for pharmacological studies. These studies have begun to describe the liver-to-plasma concentration ratio and how this ratio is altered in the setting of advanced liver disease. These data are particularly relevant to individuals with substance-use disorders because many have advanced liver disease as a consequence of long-standing viral hepatitis infection or continued use of hepatotoxins such as alcohol. Future research should attempt to develop standardized and reproducible methods to assess liver drug concentration, complex drug interactions, and pharmacogenomics in humans to permit elucidation of the clinical pharmacology within the liver.
© 2017, The American College of Clinical Pharmacology.

Entities:  

Keywords:  hepatocyte; liver drug concentration; liver drug metabolism; pharmacodynamics; pharmacokinetics

Mesh:

Substances:

Year:  2017        PMID: 28263459      PMCID: PMC5859954          DOI: 10.1002/cpdd.311

Source DB:  PubMed          Journal:  Clin Pharmacol Drug Dev        ISSN: 2160-763X


  45 in total

1.  Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition.

Authors:  K Bleasby; J C Castle; C J Roberts; C Cheng; W J Bailey; J F Sina; A V Kulkarni; M J Hafey; R Evers; J M Johnson; R G Ulrich; J G Slatter
Journal:  Xenobiotica       Date:  2006 Oct-Nov       Impact factor: 1.908

2.  Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms.

Authors:  Antonio D'Avolio; Chiara Carcieri; Jessica Cusato; Marco Simiele; Andrea Calcagno; Sarah Allegra; Mauro Sciandra; Laura Trentini; Giovanni Di Perri; Stefano Bonora
Journal:  J Antimicrob Chemother       Date:  2014-07-04       Impact factor: 5.790

3.  Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C.

Authors:  David Butera; Svetlana Marukian; Amy E Iwamaye; Edgardo Hembrador; Thomas J Chambers; Adrian M Di Bisceglie; Edgar D Charles; Andrew H Talal; Ira M Jacobson; Charles M Rice; Lynn B Dustin
Journal:  Blood       Date:  2005-04-28       Impact factor: 22.113

4.  Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

Authors:  Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant
Journal:  Sci Transl Med       Date:  2012-09-12       Impact factor: 17.956

5.  Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.

Authors:  Ana I Romero; Martin Lagging; Johan Westin; Amar P Dhillon; Lynn B Dustin; Jean-Michel Pawlotsky; Avidan U Neumann; Carlo Ferrari; Gabriele Missale; Bart L Haagmans; Solko W Schalm; Stefan Zeuzem; Francesco Negro; Elke Verheij-Hart; Kristoffer Hellstrand
Journal:  J Infect Dis       Date:  2006-08-29       Impact factor: 5.226

Review 6.  The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.

Authors:  M Zeremski; L M Petrovic; A H Talal
Journal:  J Viral Hepat       Date:  2007-10       Impact factor: 3.728

7.  Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.

Authors:  Jennifer R King; Sandeep Dutta; Daniel Cohen; Thomas J Podsadecki; Bifeng Ding; Walid M Awni; Rajeev M Menon
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

8.  Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.

Authors:  Robert B Perni; Susan J Almquist; Randal A Byrn; Gurudatt Chandorkar; Pravin R Chaturvedi; Lawrence F Courtney; Caroline J Decker; Kirk Dinehart; Cynthia A Gates; Scott L Harbeson; Angela Heiser; Gururaj Kalkeri; Elaine Kolaczkowski; Kai Lin; Yu-Ping Luong; B Govinda Rao; William P Taylor; John A Thomson; Roger D Tung; Yunyi Wei; Ann D Kwong; Chao Lin
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

9.  Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells.

Authors:  Joseph E Rower; Leah C Jimmerson; Xinhui Chen; Jia-Hua Zheng; Ariel Hodara; Lane R Bushman; Peter L Anderson; Jennifer J Kiser
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

10.  Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.

Authors:  P Badri; S Dutta; E Coakley; D Cohen; B Ding; T Podsadecki; B Bernstein; W Awni; R Menon
Journal:  Am J Transplant       Date:  2015-02-23       Impact factor: 8.086

View more
  1 in total

1.  Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.

Authors:  Matthew W McClure; Elina Berliba; Tengiz Tsertsvadze; Adrian Streinu-Cercel; Leen Vijgen; Béatrice Astruc; Alain Patat; Christopher Westland; Sushmita Chanda; Qingling Zhang; Thomas N Kakuda; Jennifer Vuong; Nick Khorlin; Leonid Beigelman; Lawrence M Blatt; John Fry
Journal:  PLoS One       Date:  2018-10-16       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.